A new study finds that novel direct-acting antiviral therapies might reduce the prevalence of hepatitis C virus and, with enhanced screening and treatment, potentially end infections altogether.
Treating hepatitis C virus (HCV) infection at early stages of fibrosis improves health outcomes and is cost-effective, a new study finds.
An easy, cost-effective, one-step test can allow clinicians to screen, detect, and confirm hepatitis C virus (HCV) infections, according to a new study.
Nearly half of all Medicaid claims for direct-acting antiviral drugs to treat chronic hepatitis C virus infections have been denied in four states recently because they were not considered “a medical necessity,” according to a new study.
Nearly all patients with chronic hepatitis C virus (HCV) infections should receive direct-acting anti-viral agents, according to updated guidelines by the American Association for the Study for Liver Diseases and the Infectious Diseases Society of America.
Clinical studies that rely on diagnostic codes or biopsies to provide evidence of cirrhosis may be underestimating the extent of the disease among hepatitis C patients, according to a new study.